Table II.

Canonical pathways in up- and downregulated breast cancer proteins.

Pathway	Ratio	Number	P-value
Upregulated
Glycolysis	0.18	15	4.88e−8
Pyruvate metabolism	0.18	11	3.52e−6
Protein ubiquitination pathway	0.09	23	1.30e−5
RhoA signaling	0.12	13	5.00e−5
NRF2-mediated oxidative stress response	0.09	17	6.71e−5
PI3K/AKT signaling	0.10	13	8.75e−5
Fatty acid metabolism	0.13	13	2.62e−4
Integrin signaling	0.08	16	2.80e−4
ILK signaling	0.08	15	2.82e−4
14-3-3-mediated signaling	0.10	12	3.10e−4
RAN signaling	0.28	5	3.16e−4
Aryl hydrocarbon receptor signaling	0.12	17	3.48e−4
Clathrin-mediated endocytosis signaling	0.08	14	6.40e−4
Valine, leucine and isoleucine degradation	0.13	8	7.71e−4
IGF-1 signaling	0.10	10	1.12e−3
VEGF signaling	0.10	9	1.75e−3
Arginine and proline metabolism	0.11	8	2.10e−3
EIF2 signaling	0.07	14	2.19e−3
Actin cytoskeleton signaling	0.07	15	2.96e−3
ERK5 signaling	0.11	7	3.55e−3
GABA receptor signaling	0.13	6	4.00e−3
Regulation of actin-based motility by Rho	0.09	8	5.16e−3
LPS/IL-1 mediated inhibition of RXR function	0.06	13	9.42e−3
HER-2 signaling in breast cancer	0.09	7	1.10e−2
Downregulated
Citrate cycle	0.09	5	1.25e−4
Acute phase response signaling	0.06	10	6.53e−4
P53 signaling	0.07	7	1.13e−3
Primary immunodeficiency signaling	0.09	5	1.80e−3
Urea cycle and metabolism of amino groups	0.13	4	2.76e−3
Cdc42 signaling	0.06	8	3.40e−3
Glyoxylate and dicarboxylate metabolism	0.18	4	1.12e−3
Autoimmune thyroid disease signaling	0.08	3	1.02e−3